Literature DB >> 22863441

Kayser-Fleischer ring in Wilson's disease: a cohort study.

M Fenu1, M Liggi, E Demelia, O Sorbello, A Civolani, L Demelia.   

Abstract

AIMS: To evaluate Wilson's disease (WD) features in Sardinian patients with Kayser-Fleischer (KF) ring and to evaluate correlations between modifications in KF and anti-copper therapy and systemic WD evolution. PATIENTS AND METHODS: Sixty-seven WD patients (35 m/32 f; mean age 41 years) were retrospectively studied. At diagnosis and during follow up comprehensive ophthalmologic and neurologic examinations, brain RMN and ECD SPECT, detailed objective laboratory studies and hepatic histological examination were performed on all patients for analysis. All patients were given anti-copper therapy with d-Penicillamine in mono-therapy or in combination with Zinc Salts.
RESULTS: At diagnosis, KF was observed in 27% of patients with equal distribution in all age groups. Significant correlations between KF at diagnosis, neuro-psychiatric manifestations and pathologic features in brain RMN and in brain ECD SPECT were found at diagnosis. During follow up, a decrease in, or regression of KF was seen in 14% of patients. Anti-copper therapy leads to KF regression and prevents the appearance of KF. No significant correlations were observed between KF regression and clinical neurological or neuro-imaging improvement nor between KF modifications and clinical hepatic improvement.
CONCLUSIONS: Our study highlights the peculiar features of Sardinian WD patients: low representation of KF, its equal distribution in all age groups, significant correlation between KF at diagnosis and clinical neurological manifestations, pathologic brain RMN and brain ECD-SPECT are highlighted by our study. Anti-copper therapy induces KF regression and prevents its onset. Therefore, KF ring does appear to be a predictive factor in the neurological and hepatic evolution of WD.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863441     DOI: 10.1016/j.ejim.2012.04.005

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

Review 1.  Clinical presentations of Wilson disease.

Authors:  Samuel Shribman; Thomas T Warner; James S Dooley
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Challenges in the diagnosis of Wilson disease.

Authors:  Aurélia Poujois; France Woimant
Journal:  Ann Transl Med       Date:  2019-04

3.  Next-generation sequencing: a decisive diagnostic aid for atypical Wilson's disease.

Authors:  Aurelia Poujois; Mathilde Renaud; Amory Jardel; Céline Bonnet; Solène Frismand-Kryloff; Jean Marie Ravel; Emmanuelle Schmitt; Mickael Alexandre Obadia; Sébastien Delassaux; Myriam Bronner
Journal:  J Neurol       Date:  2022-07-21       Impact factor: 6.682

Review 4.  Eye Involvement in Wilson's Disease: A Review of the Literature.

Authors:  Kevin Chevalier; Martine Mauget-Faÿsse; Vivien Vasseur; Georges Azar; Michaël Alexandre Obadia; Aurélia Poujois
Journal:  J Clin Med       Date:  2022-04-30       Impact factor: 4.964

Review 5.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

6.  Importance of a Liver Biopsy in the Management of Wilson Disease.

Authors:  Shinji Oe; Yuichi Honma; Kei Yabuki; Kahori Morino; Keiichiro Kumamoto; Tsuguru Hayashi; Masashi Kusanaga; Noriyoshi Ogino; Sota Minami; Michihiko Shibata; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2019-09-11       Impact factor: 1.271

Review 7.  Chelation therapy in liver diseases of childhood: Current status and response.

Authors:  Jayendra Seetharaman; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.